Four distinctly American features of the biosimilars market have limited uptake: A slow regulatory process, originator company behavior, lack of therapeutic interchangeability designation, and insufficient system-wide education efforts to overcome physician and patient doubts.
What’s Holding Back Market Uptake Of Biosimilars?
